Innovative Neurotherapy GeNeuro focuses on developing treatments targeting neurodegenerative and autoimmune disorders related to Human Endogenous Retroviruses, highlighting opportunities to engage with specialized healthcare providers and research institutions dedicated to MS, ALS, and long COVID solutions.
Recent Funding Boost With recent capital raises of over 5 million euros, GeNeuro is expanding its clinical trial pipeline and research initiatives, presenting prospects for investors and strategic partners interested in early-stage biotech innovations in neurological health.
Clinical Trial Progress The successful launch and advancement of multiple Phase 2 trials for therapies like temelimab suggest potential to introduce new neuroprotective products to hospitals, clinics, and specialty treatment centers focused on MS and long COVID management.
Strategic Partnerships Partnerships with institutions like the European Investment Bank and collaborations with NINDS signal opportunities for co-development, licensing agreements, and joint ventures within the neurological therapeutics space targeting high unmet medical needs.
Market Expansion Potential GeNeuro's focus on conditions with increasing prevalence such as MS and long COVID positions the company for growth, offering sales opportunities in both clinical and final consumer markets as treatments progress through trials to commercialization.
$1M$10M
$1M$10M
$10M$25M
$1M$10M
$10M$25M
$1M$10M
$1M$10M
$500M$1B
$50M$100MGeNeuro SA uses 8 technology products and services including Linkedin Insight Tag, WordPress, imagesLoaded, and more. Explore GeNeuro SA's tech stack below.
| GeNeuro SA Email Formats | Percentage |
| First.Last@geneuro.com | 44% |
| FL@geneuro.com | 9% |
| Last.First@geneuro.com | 3% |
| First.Last@geneuro.com | 44% |
Biotechnology ResearchSwitzerland11-50 Employees
GeNeuro is a biotechnology company developing innovative treatments against inflammatory and neurodegenerative disorders associated with Human Endogenous Retroviruses (HERVs). We are committed to fight the progression of disability in Multiple Sclerosis #FightMS and other neurodegenerative diseases #ALS #LongCOVID Our Community Guidelines: http://bit.ly/36y9YCE
Company Overview
Funding & FinancialsGeNeuro SA has raised a total of $5.4M of funding over 7 rounds. Their latest funding round was raised on Feb 01, 2024 in the amount of $5.4M.
GeNeuro SA's revenue is estimated to be in the range of $1M
Funding & FinancialsGeNeuro SA has raised a total of $5.4M of funding over 7 rounds. Their latest funding round was raised on Feb 01, 2024 in the amount of $5.4M.
GeNeuro SA's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com